US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

AbbVie Inc.

ABBVNYSE

143.06

USD
+0.05
(+0.03%)
Market Closed
20.23P/E
12Forward P/E
1.01P/E to S&P500
252.944BMarket CAP
3.87%Div Yield

AbbVie Inc.

NYSE:ABBV

RECENT
PRICE

143.06

P/E
RATIO

20.23

(PEG:0.14)

P/E RATIO
RELATIVE
TO S&P

1.01

DIV
YLD

3.87%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

0.69 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 09/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

- -

- -

- -

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

9.00

2.93

3.20

- -

9.90

2.64

2.87

- -

11.04

2.17

3.73

- -

11.66

3.34

3.81

- -

11.84

2.60

3.64

1.61

12.54

1.11

1.85

1.67

14.20

3.20

4.35

2.05

16.10

3.74

4.12

2.33

17.72

3.33

5.92

2.58

22.15

3.85

8.65

3.77

22.49

5.33

8.64

4.30

25.95

2.62

9.51

4.37

31.84

6.54

12.46

5.25

32.41

7.13

12.56

5.46

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

- -

- -

- -

- -

- -

- -

0.20

- -

0.28

9.94

0.23

7.74

0.21

2.13

0.31

2.83

0.38

1.09

0.33

2.45

0.30

2.91

0.33

3.20

0.43

(5.71)

0.37

(5.53)

0.45

7.41

0.45

8.73

0.40

8.46

CAPEX per share

Book Value per share

- -

- -

- -

1,580

1,580

1,580

1,577

1,587

1,591

1,610

1,593

1,592

1,479

1,479

1,765

1,765

1,769

Comm.Shares outs.(m)

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

- -

16.7

1.0

3.7%

49.7

2.7

3.0%

19.2

1.0

3.3%

16.1

0.7

3.9%

22.4

1.0

3.4%

25.3

1.0

3.9%

14.5

0.6

5.6%

34.4

0.9

4.9%

17.3

0.6

4.6%

20.2

1.0

3.9%

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (30/6/22 | Q2)

Total liabilities
$128,498 m.

Total assets
$143,186 m.

Long-term debt
$61,002 m.

Cash and equiv.
$8,521 m.

Goodwill $32,028 m.

Retained earnings $3,516 m.

Common stock 1,770 m. shares

Market Capitalisation
$252,944 m. (as of 24/9/22)

17,444

20.8%

18,380

31.6%

18,790

30.1%

19,960

17.1%

22,859

33.0%

25,638

36.6%

28,216

34.0%

32,753

19.5%

33,266

39.0%

45,804

24.8%

56,197

31.9%

57,349

30.4%

Revenue (m)

Operating margin

1,272

3,433

1,150

5,275

897

4,128

786

1,774

836

5,144

1,189

5,953

1,501

5,309

1,765

5,687

2,017

7,882

6,471

4,616

8,521

11,542

8,211

12,637

Depreciation (m)

Net profit (m)

6.4%

19.7%

7.9%

28.7%

22.6%

22.0%

25.1%

8.9%

22.6%

22.5%

24.5%

23.2%

31.3%

18.8%

(9.4)%

17.4%

6.5%

23.7%

(36.0)%

10.1%

11.1%

20.5%

12.4%

22.2%

Income tax rate

Net profit margin

1,457

- -

12,224

8,578

14,630

3,363

10,969

14,292

4,492

4,688

10,565

1,742

5,420

29,240

3,945

6,406

36,440

4,636

4,582

30,953

5,097

(294)

35,002

(8,446)

33,934

62,975

(8,172)

(4,488)

77,554

13,076

(7,266)

64,189

15,408

(5,373)

61,002

14,653

Working capital (m)

Long-term debt (m)

Equity (m)

24.9%

18.7%

28.1%

26.5%

21.6%

156.9%

19.5%

19.3%

91.9%

13.0%

10.2%

101.8%

13.5%

13.9%

130.4%

12.0%

13.5%

128.4%

11.3%

12.5%

104.2%

17.0%

11.0%

(67.3)%

13.0%

11.5%

(96.5)%

6.5%

3.9%

35.3%

12.3%

10.5%

74.9%

13.2%

11.4%

86.2%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

39,924

8,449

9,746

Receivables

5,428

8,822

9,977

Inventory

1,813

3,310

3,128

Other

2,354

3,562

4,993

Current assets

49,519

24,173

27,928

Acc. Payable

1,452

2,276

2,882

Debt due

3,753

8,502

12,495

Other

10,380

17,883

19,817

Current liab.

15,585

28,661

35,194

100.0%

- -

100.0%

- -

38.1%

49.8%

(50.0)%

112.8%

36.0%

155.1%

37.6%

148.6%

22.6%

58.5%

1.9%

137.6%

19.2%

54.8%

(67.2)%

51.8%

19.8%

46.4%

23.6%

50.8%

Plowback ratio

Div.&Repurch. to FCF

AbbVie Inc. (US) started trading on January 3, 2013 (cik: 0001551152), operates in the Healthcare sector (Drug Manufacturers—General industry), has 50,000 full-time employees, and is led by Mr. Richard Gonzalez. AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

19.51%

13.69%

Cash flow

24.48%

24.52%

Earnings

38.58%

30.05%

Dividends

22.80%

- -

Book value

-127.78%

-42.76%

Insider trading

Type

Shares

Date

Rapp Edward J

Award

237

06/30/22

Alpern Robert J

Award

47

06/30/22

Severino Michael

Exempt

21,739

05/23/22

Severino Michael

Exempt

11,742

05/23/22

Severino Michael

Exempt

46,320

05/23/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

8,619

10,425

12,902

13,858

45,804

2021

13,010

13,959

14,342

14,886

56,197

2022

13,538

14,583

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

1.71

(0.42)

1.31

0.02

2.62

2021

2.01

0.43

1.80

2.29

6.54

2022

2.54

0.52

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

1.00

0.99

1.19

1.19

4.37

2021

1.32

1.31

1.31

1.31

5.25

2022

1.43

1.42

- -

- -

- -

07/07/2022

Senate Report Hits AbbVie’s Bermuda Tax Structure for U.S. Humira Sales

The Wall Street Journal - Read more...

04/18/2022

J&J Settles With West Virginia in Opioid Suit for $99 Million

The Wall Street Journal - Read more...

02/02/2022

Alphabet, PayPal, AMD, Meta, Starbucks: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

12/08/2021

Allergan Reaches $200 Million Opioid Settlement With New York Authorities

The Wall Street Journal - Read more...

11/02/2021

Opioid Manufacturers Score Win in California Lawsuit

The Wall Street Journal - Read more...

10/29/2021

Apple, Amazon, Lucid, Chevron: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

07/30/2021

Amazon, Pinterest, Robinhood, Chevron: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

05/18/2021

House Committee Takes On Pricing, Patents for Top-Selling Drug Humira

The Wall Street Journal - Read more...

04/30/2021

Twitter, Amazon, Clorox, Chevron: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

10/16/2020

NIH to Study Three Drugs in Treatment of Covid Patients

The Wall Street Journal - Read more...